The ReWalk Exoskeletal Walking System for Persons With Paraplegia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2015-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is well appreciated that an extreme sedentary lifestyle from paralysis, contributes to many secondary medical problems such as diabetes and insulin resistance, obesity, constipation, poor blood pressure regulation, cardiovascular disease, reduced quality of life, and more. The ReWalk-I exoskeleton walking device permits investigation of the potential benefits of frequent upright posture and walking on many of the secondary consequences of spinal cord injury. The researchers are investigating the ability of persons with paraplegia to learn to stand and walk with the ReWalk-I and the effects of being upright and walking on several of these secondary medical consequences of spinal cord injury.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Powered Exoskeletons in Persons With SCI

NCT02658656

Spinal Cord Injury

COMPLETED NA

A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit

NCT00627107

Paraplegia SCI

COMPLETED NA

Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI

NCT02314221

Spinal Cord Injury Paraplegia Tetraplegia

COMPLETED NA

Home/Work, Community Mobility Skills in the ReWalk Exoskeleton in Persons With SCI

NCT02118194

Spinal Cord Injury

COMPLETED

Exoskeletons for Spinal Cord Injury: A Feasibility Study

NCT01943669

Spinal Cord Injury

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Potential participants will be pre-screened with the inclusion criteria for eligibility. The informed consent process will begin for those participants who have been determined to meet the inclusion criteria. After the potential participant's signed consent has been provided, further evaluations for eligibility will be performed (e.g., there are several medical and physical exclusion criteria). Those potential participants who meet both the inclusion and exclusion criteria will be eligible to enroll into the ReWalk-I study. Baseline evaluations and personalized measurements for fitting to the ReWalk-I will be performed over one week, before the training sessions begin. The ReWalk sessions will consist of a Learning Phase (12 sessions in 4 weeks) and a Training Phase (18 sessions in 6 weeks). These times may vary by each participant's ReWalk learning curve. Training will begin with sit-to-stand, stand-to-sit, and standing balance activities. Progression to walking will occur as skills advance. Each session will be an average 50 minutes, with 3 sessions per week. The skills to be learned include 1) sit-to-stand, 2) stand-to-sit, 3) 2-arm standing balance, 4) 1-arm standing balance, 5) walking, and 6) stair climbing. The study evaluations will be repeated after the Learning Phase, after the Training Phase and 1-month post training follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paraplegia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Powered Exoskeleton

persons with SCI trained to use a powered exoskeleton to ambulate overground

Group Type EXPERIMENTAL

powered exoskeleton

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

powered exoskeleton

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females with paraplegia
2. Duration of SCI \>6 months
3. Ages 18 to 65 y
4. Height 160 to 190cm (63-75in or 5'3" to 6'3")
5. Weight \<100kg (\<220 lb)
6. Ability to give informed consent

Exclusion Criteria

1. Diagnosis of neurological injury other than SCI including:

* Multiple sclerosis (MS)
* Stroke
* Cerebral Palsy (CP)
* Amyotrophic lateral sclerosis (ALS)
* Traumatic Brain injury (TBI)
* Spina bifida
* Parkinson's disease (PD)
* Other neurological condition that the study physician considers in his/her clinical judgment to be exclusionary
2. Severe concurrent medical disease, illness or condition
3. Recent lower extremity fracture within the past 2 years;
4. DXA results indicating a t-score below -3.0 and knee BMD \<0.70 gm/cm2
5. Systemic or peripheral infection
6. Atherosclerosis, congestive heart failure, or history of myocardial infarction
7. Trunk and/or lower extremity pressure ulcers;
8. Other illness, that the study physician considers in his/her clinical judgment to be exclusionary
9. Severe spasticity (defined by an Ashworth score of \>4.0 or clinical impression of the study physician or physical therapist)
10. Significant contractures defined as flexion contracture limited to 35º at the hip and 20º at the knee;
11. Diagnosis of heterotrophic ossification of the lower extremities;
12. Femoral neck or the total proximal femur bone mineral density T-scores \< -3.0
13. Psychopathology documentation in the medical record or history of that may conflict with study objectives
14. Hypertension (SBP\>140, DBP\>90)
15. Pregnancy and/or lactating females

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No